Kura Oncology remains a Strong Buy, driven by Ziftomenib's differentiated safety profile and significant AML market potential. KURA's Ziftomenib avoids a QTc prolongation boxed warning, offering a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback